This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Gaudium, Cipralex, Sipralexa, Seroplex, MLD-55, Entact
Lexapro (escitalopram oxalate) is an orally administered selective serotonin reuptake inhibitor (SSRI). Lexapro is the single-active isomer of Celexa, a racemic mixture with two mirror-image halves called the S- and R-enantiomers.
Lexapro acts by inhibiting CNS neuronal reuptake of serotonin leading to increased levels of serotonin in the brain. It has little effect on norepinephrine and dopamine.
Escitalopram was originally developed by Lundbeck and Forest.
Lundbeck and Mitsui
In August 2000, H. Lundbeck A/S and Mitsui Pharmaceuticals signed a semi-exclusive licence agreement on the development, registration, sale and marketing of citalopram on the Japanese market.
Lundbeck and Recordati
In January 2002, Recordati announced that it has entered into a semi-exclusive agreement with Lundbeck for the marketing and sale in Italy of escitalopram (Gaudium), indicated for the treatment of depression and panic disorders. This new agreement was reached as a follow-up to the previous license for citalopram (Elopram/Seropram), the antidepressant launched in Italy in co-marketing with Lundbeck in 1995.
In January 2014, Recordati announced that organic growth will be impacted by the termination of the license agreement for Entact (escitalopram) in Italy as a result of the products patent expiry.
Lundbeck and Mochida
In May 2002,...See full deal structure in Biomedtracker
Partners: H. Lundbeck A/S Mochida Pharmaceutical Co., Ltd. Mitsubishi Tanabe Pharma Corporation Almirall Prodesfarma, S.A. Abbott Laboratories
Additional information available to subscribers only: